Phase II trial of nab-paclitaxel plus ramucirumab in combination with nivolumab for unresectable advanced or recurrent gastric cancer after progression on first-line treatment including fluoropyrimidine, platinum, and anti-PD-1/PD-L1 antibody (PADDLE

Authors

Kengo Nagashima (ORCID: https://orcid.org/0000-0003-4529-9045)
Nobumi Suzuki (ORCID: https://orcid.org/0000-0001-9566-8828)
Hidekazu Hirano (ORCID: https://orcid.org/0000-0003-1343-1419)
Takeshi Kawakami (ORCID: https://orcid.org/0000-0001-9385-9516)
Naoki Takahashi (ORCID: https://orcid.org/0000-0001-6377-9507)
Daisuke Takahari (ORCID: https://orcid.org/0000-0002-2492-6014)
Yusuke Amanuma
Chie Kudo‐Saito (ORCID: https://orcid.org/0000-0003-4644-9404)
Ken Kato (ORCID: https://orcid.org/0000-0002-1733-5072)
Hirokazu Shoji
Narikazu Boku

Institutions

Shizuoka Cancer Center (JP)
National Cancer Center (US)
Keio University Hospital (JP)
Tokyo Medical University Hospital (JP)
Chiba Cancer Center (JP)
Saitama Cancer Center (JP)
Japanese Foundation For Cancer Research (JP)
The University of Tokyo (JP)

Publication Details

Journal: BMC Cancer
Published: 2025-02-04
DOI: https://doi.org/10.1186/s12885-025-13591-5
Citations: 4
Primary Topic: Gastric Cancer Management and Outcomes
Type: article
Field-Weighted Citation Impact: 6.07

Funders

Ono Pharmaceutical

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

Phase II trial of nab-paclitaxel plus ramucirumab in combination with nivolumab for unresectable advanced or recurrent gastric cancer after progression on first-line treatment including fluoropyrimidine, platinum, and anti-PD-1/PD-L1 antibody (PADDLE

Kengo Nagashima, Nobumi Suzuki, Hidekazu Hirano, Takeshi Kawakami et al.

Feb 4, 2025

4 citations

BMC Cancer

Gastric Cancer Management and Outcomes

6.07

article

Phase II trial of nab-paclitaxel plus ramucirumab in combination with nivolumab for unresectable advanced or recurrent gastric cancer after progression on first-line treatment including fluoropyrimidine, platinum, and anti-PD-1/PD-L1 antibody (PADDLE

Kengo Nagashima, Nobumi Suzuki, Hidekazu Hirano, Takeshi Kawakami, Naoki Takahashi, Daisuke Takahari, Yusuke Amanuma, Chie Kudo‐Saito, Ken Kato, Hirokazu Shoji, Narikazu Boku

February 4, 2025article en

4 citations

Abstract

No abstract available for this paper.

BMC CancerVol. 25(1)

Shizuoka Cancer Center (JP), National Cancer Center (US), Keio University Hospital (JP), Tokyo Medical University Hospital (JP), Chiba Cancer Center (JP), Saitama Cancer Center (JP), Japanese Foundation For Cancer Research (JP), The University of Tokyo (JP)

Ono Pharmaceutical

Good health and well-being

Openalex Percentile: Top 4%

Gastric Cancer Management and Outcomes

6.07

DOI Open Access PDF OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.